A single-center, open, single-arm clinical study on the safety and effectiveness of CAR-T cell therapy for relapsed/refractory tumours of haematopoietic and lymphoid tissues

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000041436

Enrollment

Unknown

Registered

2020-12-26

Start date

2020-12-28

Completion date

Unknown

Last updated

2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed/refractory tumours of haematopoietic and lymphoid tissues

Interventions

experimental group:CAR-T

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients or their legal guardians voluntarily participate and sign the informed consent; 2. Male or female patients aged from 18 to 70 years (including 18 and 70 years); 3. Patients with relapsed and refractory lymphoid hematopoietic system tumors confirmed by pathology and / or flow cytometry as positive for CD19, CD20, CD22, CD30, CD79b, CD99, CD38, CD7 and BCMA; 4. Patients who have no effective treatment, such as relapse after standard chemotherapy or hematopoietic stem cell transplantation, voluntarily choose car-t cell therapy as salvage treatment; 5. Patients whose estimated survival time is more than 3 months.

Exclusion criteria

Exclusion criteria: 1. Women in pregnancy (positive urine / blood pregnancy test) or lactation period; 2. Men or women who have plans to conceive in the past year; 3. The patients could not take effective contraceptive measures (condom or contraceptive, etc.) within one year after enrollment; 4. Patients with uncontrollable infectious diseases within 4 weeks before enrollment; 5. Patients with active hepatitis B / C; 6. HIV infected patients; 7. Patients with severe autoimmune diseases or immunodeficiency diseases; 8. Patients with allergic constitution are allergic to macromolecular biological drugs such as antibodies or cytokines; 9. Patients who participated in other clinical trials within 6 weeks before enrollment; 10. Patients with mental illness; 11. Patients with drug abuse / addiction; 12. According to the judgment of the researcher, the patients were not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
safety;	—

Secondary

Measure	Time frame
efficacy;	—

Countries

China

Contacts

Public ContactHong Cen

Cancer Hospital Affiliated to Guangxi Medical University

cen_hong@163.com+86 13507711671

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026